Single agent etoposide in gestational trophoblastic tumours

Hitchins, R. N.; Holden, L.; Newlands, E. S.; Begent, R. H. J.; Rustin, G. J. S.; Bagshawe, K. D.

doi:10.1016/0277-5379(88)90156-3

Cited by 16 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of a large, consecutive case series of 272 patients with up to 16 years of follow-up showed a complete remission rate of 78% using this regimen, and these results are consistent with other case series in the literature that employed EMA/CO [43]. More than two-thirds of the women who did not have a complete response or subsequently had disease recurrence could be salvaged with cisplatin-containing regimens (with or without resection of metastases), yielding a long-term cure rate of 86.2% (95% CI, 81.9%-90.5%) [39].…”

Section: Management Of High-risk Gtnsupporting

confidence: 77%

“…a Adapted from Bower et al [43] b Adapted from Escobar et al [44] c Adapted from Lurain et al [45] Table 4. Low-/high-risk post-chemotherapy patients, hCG concentration sampling.…”

Section: Management Of High-risk Gtnmentioning

confidence: 99%

“…However, even patients with brain metastases may achieve long-term remission in 50% to 80% of cases [43,44,49] Patients with Central Nervous System (CNS) metastases receive additional therapy simultaneously with the initiation of systemic chemotherapy. Some centers utilize whole-brain irradiation (30 Gy in 2 Gy fractions) with or without intrathecal methotrexate [47].…”

Section: Management Of High-risk Gtnmentioning

confidence: 99%

“…Therefore, the literature does not permit firm conclusions about the best chemotherapeutic regimen [41]. However, since EMA/CO (i.e., etoposide, methotrexate, and dactinomycin/cyclophosphamide and vincristine) is the most commonly used regimen, the specifics are provided in Table below [43][44][45].…”

Section: Management Of High-risk Gtnmentioning

confidence: 99%

See 3 more Smart Citations

Management of gestational trophoblastic neoplasia

Hussain¹,

Aziz²,

Mohd³

et al. 2015

Clin Obstet Gynecol Reprod Med

View full text Add to dashboard Cite

Section: Management Of High-risk Gtnsupporting

confidence: 77%

“…a Adapted from Bower et al [43] b Adapted from Escobar et al [44] c Adapted from Lurain et al [45] Table 4. Low-/high-risk post-chemotherapy patients, hCG concentration sampling.…”

Section: Management Of High-risk Gtnmentioning

confidence: 99%

Section: Management Of High-risk Gtnmentioning

confidence: 99%

Section: Management Of High-risk Gtnmentioning

confidence: 99%

See 2 more Smart Citations

Management of gestational trophoblastic neoplasia

Hussain¹,

Aziz²,

Mohd³

et al. 2015

Clin Obstet Gynecol Reprod Med

View full text Add to dashboard Cite

“…Of these chemotherapeutic regimens, Hitchins et al . ( 5 ) reported that VP‐16 regimens should be reserved either for patients in whom MTX resistance has developed or for patients initially classified into the medium‐ or high‐risk groups in view of the unknown long‐term potential side‐effects of VP‐16, such as ovarian dysfunction, impaired fertility, and future potential of second malignancies. We have previously reported that the known short‐term side‐effects of VP‐16 were acceptable, except for alopecia ( 6 ) .…”

mentioning

confidence: 99%

Pregnancy outcome after treatment with etoposide (VP-16) for low-risk gestational trophoblastic tumor

Matsui

Iitsuka

Seki

et al. 1999

Int J Gynecol Cancer

View full text Add to dashboard Cite

The aim of this study was to evaluate subsequent fertility and pregnancy in patients treated for persistent trophoblastic tumors with single-agent VP-16. Records of all patients treated for persistent trophoblastic tumors at the Chiba University Hospital between January 1, 1986 and December 31, 1997 were reviewed. Of these, 85 patients were initially treated with single-agent VP-16. Subsequent pregnancy outcome of these patients was investigated. After remission with VP-16, 36 patients (92.3%) of those who wished for a pregnancy (45.9% of all patients studied) conceived, and 91.7% had at least one live birth. A total of 56 conceptions resulted in 42 (75.0%) term live births, seven (12.5%) first-trimester spontaneous abortions, one (1.8%) second-trimester spontaneous abortion, four (7.1%) therapeutic abortions, and two (3.6%) repeated moles. There were no congenital anomalies, no stillbirths, and the neonates' physical growth was comparable to that of the standard population in Japan. Single VP-16 regimen for patients with low-risk gestational trophoblastic tumor appears to have no adverse effects on fertility potential and pregnancy outcome.

show abstract

First line chemotherapy in low risk gestational trophoblastic neoplasia

Alazzam¹,

Tidy²,

Hancock³

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background-This is an update of a Cochrane review that was first published in Issue 1, 2009. Gestational trophoblastic neoplasia (GTN) is a rare but curable disease arising in the fetal chorion during pregnancy. Most women with low-risk GTN will be cured by evacuation of the uterus with or without single-agent chemotherapy. However, chemotherapy regimens vary between treatment centres worldwide and the comparable benefits and risks of these different regimens are unclear.

show abstract

Single agent etoposide in gestational trophoblastic tumours

Cited by 16 publications

References 13 publications

Management of gestational trophoblastic neoplasia

Management of gestational trophoblastic neoplasia

Pregnancy outcome after treatment with etoposide (VP-16) for low-risk gestational trophoblastic tumor

First line chemotherapy in low risk gestational trophoblastic neoplasia

Contact Info

Product

Resources

About